MorphoSys Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jean-Paul Kress

Chief Executive Officer (CEO)

€4.8m

Compensación total

Porcentaje del salario del CEO	18.1%
Permanencia del CEO	4.6yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

Apr 17

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Nov 26

News Flash: 10 Analysts Think MorphoSys AG (ETR:MOR) Earnings Are Under Threat

Mar 21

MorphoSys AG (ETR:MOR) Analysts Just Slashed Next Year's Revenue Estimates By 10%

Jan 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jean-Paul Kress en comparación con los beneficios de MorphoSys?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€5m	€864k	-€190m
Sep 30 2023	n/a	n/a	€91m
Jun 30 2023	n/a	n/a	€88m
Mar 31 2023	n/a	n/a	-€73m
Dec 31 2022	€5m	€797k	-€151m
Sep 30 2022	n/a	n/a	-€861m
Jun 30 2022	n/a	n/a	-€851m
Mar 31 2022	n/a	n/a	-€596m
Dec 31 2021	€2m	€770k	-€514m
Sep 30 2021	n/a	n/a	-€150m
Jun 30 2021	n/a	n/a	-€103m
Mar 31 2021	n/a	n/a	-€177m
Dec 31 2020	€3m	€723k	€98m
Sep 30 2020	n/a	n/a	€64m
Jun 30 2020	n/a	n/a	€105m
Mar 31 2020	n/a	n/a	€153m
Dec 31 2019	€4m	€233k	-€103m

Compensación vs. Mercado: La compensación total de Jean-Paul($USD5.09M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD2.38M).

Compensación vs. Ingresos: La compensación de Jean-Paul ha sido consistente con los resultados de la empresa en el último año.

CEO

Jean-Paul Kress (58 yo)

4.6yrs

Permanencia

€4,764,900

Compensación

Dr. Jean-Paul Kress, M.D. has been the Chief Executive Officer of MorphoSys AG since September 1, 2019 and has been its Management Board Member since 2019 and serves as its Chairman of Management Board and...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jean-Paul Kress	Chairman of Management Board	4.6yrs	€4.76m	sin datos
Lucinda Crabtree	CFO & Member of Management Board	1.3yrs	€1.51m	sin datos
Charlotte Lohmann	Chief Legal and Human Resources Officer & Member of Management Board	4.3yrs	€1.10m	0.0036% € 88.8k
Klaus De Wall	Head of Accounting & Tax	no data	sin datos	sin datos
Margit Urban	Head of Discovery Alliances & Technologies	no data	sin datos	sin datos
Julia Neugebauer	Head of Investor Relations	no data	sin datos	sin datos
Barbara Krebs-Pohl	Chief Business Officer	no data	sin datos	sin datos
Günter Wellnhofer	Head of Technical Operations	no data	sin datos	sin datos
Harald Watzka	Head of Alliance Management	no data	sin datos	sin datos
Yen Ching Chua	Head of Clinical Operations	no data	sin datos	sin datos
Kathrin Tissot	Head of Business Team	no data	sin datos	sin datos
Thomas Biegi	Senior VP & Head of Corporate Affairs	less than a year	sin datos	sin datos

2.8yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MOR se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Brosnan	Independent Member of the Supervisory Board	5.9yrs	€116.90k	0.013% € 328.4k
Marc Cluzel	Independent Chairman of the Supervisory Board	11.9yrs	€160.20k	0.023% € 559.8k
Andrew Cheng	Independent Member of Supervisory Board	1.9yrs	€80.10k	sin datos
Bruce Cheson	Member of Scientific Advisory Board	7.6yrs	sin datos	sin datos
George Golumbeski	Independent Deputy Chairman of Supervisory Board	5.9yrs	€100.10k	sin datos
Gunther Adolf	Member of Scientific Advisory Board	7.6yrs	sin datos	sin datos
Sergio Quezada	Member of Scientific Advisory Board	7.6yrs	sin datos	sin datos
Raymond Sweet	Member of Scientific Advisory Board	7.6yrs	sin datos	sin datos
Krisja Vermeylen	Independent Member of the Supervisory Board	6.9yrs	€96.50k	0.0080% € 197.1k
Sharon Curran	Independent Member of Supervisory Board	4.8yrs	€92.60k	sin datos

7.3yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de MOR se considera experimentada (7.3 años de antigüedad promedio).

MorphoSys Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

MorphoSys AG Announces Executive Changes

MorphoSys AG Announces Supervisory Board Changes

Recent updates

Consensus EPS estimates upgraded to €3.87 loss, revenue downgraded

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Profitability

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Price target increased by 13% to €35.50

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 16%

New minor risk - Shareholder dilution

MorphoSys AG's (ETR:MOR) 93% Share Price Surge Not Quite Adding Up

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Investor sentiment improves as stock rises 43%

Consensus EPS estimates fall by 12%, revenue upgraded

Price target decreased by 8.7% to €31.78

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 17%

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Investor sentiment improves as stock rises 16%

Morphosys AG Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Price target increased by 8.0% to €31.61

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

Is MorphoSys (ETR:MOR) Weighed On By Its Debt Load?

MorphoSys AG Provides Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 12% to €25.94

Consensus EPS estimates upgraded to €6.45 loss

Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?

Consensus estimates of losses per share improve by 12%

Price target increased by 7.3% to €19.64

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 27% to €18.25

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

Price target decreased to €24.05

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Price target decreased to €26.50

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to €32.45

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

Price target decreased to €37.06

MorphoSys AG Announces Executive Changes

Consensus EPS estimates fall by 48%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

Price target decreased to €40.56

MorphoSys AG Confirms Financial Guidance for the Year 2022

MorphoSys AG Announces Supervisory Board Changes

Price target decreased to €44.67

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to €44.40

Consensus forecasts updated

Price target decreased to €54.00

News Flash: 10 Analysts Think MorphoSys AG (ETR:MOR) Earnings Are Under Threat

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to €59.68